Form 4: VolitionRx Director Ethel Rubin Awarded Restricted Stock Units as Compensation

VolitionRx Ltd. Director Ethel Rubin was awarded 11,983 restricted stock units (RSUs) on June 1, 2025, as non-cash compensation under the company's 2015 Stock Incentive Plan.

Summary

• Ethel Rubin, a Director of VolitionRx Ltd. (VNRX), was awarded 11,983 restricted stock units (RSUs) on June 1, 2025.
• These RSUs were granted under the company's 2015 Stock Incentive Plan and serve as compensation in lieu of cash.
• The RSUs will vest in three installments: 3,995 units on June 1, 2025, 3,994 units on July 1, 2025, and 3,994 units on August 1, 2025.
• The award is also subject to further time-based vesting in a single installment on August 1, 2025, and generally requires continued service through each vesting date.
• Upon vesting and settlement, Ms. Rubin will receive an equivalent number of shares of common stock.
• Following this transaction, Ms. Rubin beneficially owns 45,524 shares of common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The RSU award aligns director interests with shareholders and conserves cash, which are positive. However, it's a routine compensation event and doesn't indicate significant new developments for the company's operations or financial performance.

Positives

• The award of restricted stock units aligns the director's interests with those of shareholders by tying compensation to the company's stock performance.
• The use of RSUs in lieu of cash compensation can help conserve the company's cash reserves.

Negatives

• The issuance of new shares upon vesting will result in a minor dilution for existing shareholders, although the amount is relatively small.

Risks

• The value of the compensation to the director is dependent on the future stock price of VolitionRx Ltd., introducing market risk for the recipient.
• The vesting is contingent on continued service, meaning the director must remain with the company to fully realize the award.

Future Outlook

The awarded restricted stock units are scheduled to vest in three installments on June 1, 2025, July 1, 2025, and August 1, 2025, contingent upon continued service, leading to the future issuance of common stock shares.

Industry Context

This transaction is a routine disclosure of equity compensation for a director, a common practice across publicly traded companies to align executive and board member interests with shareholder value. It does not reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• Equity compensation, such as Restricted Stock Units (RSUs), is a standard practice for compensating directors and executives in publicly traded companies across various industries, including biotechnology and diagnostics like VolitionRx.
• While specific RSU amounts vary based on company size, performance, and individual roles, the mechanism of granting RSUs in lieu of cash compensation is a widely adopted corporate governance tool.
• There are no specific comparable companies or projects mentioned in this Form 4 to provide a detailed comparative analysis of the RSU grant size.

Corporate Governance

Related Party Transactions

• The award of 11,983 restricted stock units to Ethel Rubin, a director of VolitionRx Ltd., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting of RSUs, but also improved alignment of director incentives with shareholder interests.

Next Steps

• Vesting of 3,995 RSUs on June 1, 2025.
• Vesting of 3,994 RSUs on July 1, 2025.
• Vesting of 3,994 RSUs and final time-based vesting on August 1, 2025.
• Settlement of vested RSUs into common stock shares.

Key Dates

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSU, Director Compensation, Stock Incentive Plan, SEC Form 4, Beneficial Ownership, Equity Compensation